View All Updates
On December 14, 2023, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) for the monoclonal antibody therapy Bamlanivimab/Etesevimab. In addition, all Bamlanivimab/Etesevimab supplies are now expired.
COVID-19 Therapeutics